Positive Correlation of Osteopontin, Cyclooxygenase-2 and Vascular Endothelial Growth Factor in Gastric Cancer

REFERENCES

• Rangaswami H., Bulbule A., Kundu G. C. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006; 16: 79–87
   PubMed Web of Science ®Google Scholar
• Coppola D., Szabo M., Boulware D., Muraca P., Alsarraj M., Chambers A. F., Yeatman T. J. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004; 10: 184–190
   PubMed Web of Science ®Google Scholar
• Forootan S. S., Foster C. S., Aachi V. R., Adamson J., Smith P. H., Lin K., Ke Y. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006; 118(9)2255–2261
   PubMed Web of Science ®Google Scholar
• Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A. F, Szabo M., Cantor A., Coppola D., Yeatman T. J. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002; 94(7)513–521
   PubMed Web of Science ®Google Scholar
• Lee S., Baek M., Yang H., Bang Y. J., Kim W. H., Ha J. H., Kim D. K., Jeoung D. I. Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. Cancer Lett. 2002; 184(2)197–206
   PubMed Web of Science ®Google Scholar
• Ue T., Yokozaki H., Kitadai Y., Yamamoto S., Yasui W., Ishikawa T., Tahara E. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998; 79(2)127–132
   PubMed Web of Science ®Google Scholar
• Howe L. R., Chang S. H., Tolle K. C., Dillon R., Young L. J., Cardiff R. D., Newman R. A., Yang P., Thaler H. T., Muller W. J., Hudis C., Brown A. M., Hla T., Subbaramaiah K., Dannenberg A. J. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 2005; 65(21)10113–10119
   PubMed Web of Science ®Google Scholar
• Chang Y. J., Wu M. S., Lin J. T., Sheu B. S., Muta T., Inoue H., Chen C. C. Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation. Mol Pharmacol. 2004; 66(6)1465–1477
   PubMed Web of Science ®Google Scholar
• Lim H. Y., Joo H. J., Choi J. H., Yi J. W., Yang M. S., Cho D. Y., Kim H. S., Nam D. K., Lee K. B., Kim H C. Increased Expression of Cyclooxygenase-2 Protein in Human Gastric Carcinoma. Clin Cancer Res. 2000; 6(2)519–525
   PubMed Web of Science ®Google Scholar
• Chu J., Lloyd F. L., Trifan O. C., Knapp B., Rizzo M. T. Potential Involvement of the Cyclooxygenase-2 Pathway in the Regulation of Tumor-associated Angiogenesis and Growth in Pancreatic Cancer. Mol Cancer Ther. 2003; 2(1)1–7
   PubMed Web of Science ®Google Scholar
• Tsujii M., Kawano S., DuBois R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94(7)3336–3340
   PubMed Web of Science ®Google Scholar
• Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol. 2004; 14(2)139–145
   PubMed Web of Science ®Google Scholar
• Zhang J., Peng B., Chen X. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res. 2005; 11(20)7334–7343
   PubMed Web of Science ®Google Scholar
• Liu N., Bi F., Pan Y., Sun L., Xue Y., Shi Y., Yao X., Zheng Y., Fan D. Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res. 2004; 10(18 Pt 1)6239–6247
   PubMed Web of Science ®Google Scholar
• Allred D. C., Clark G. M., Elledge R., Fuqua S. A., Brown R. W., Chamness G. C., Osborne C. K., McGuire. Association W. L.of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993; 85(3)200–206
   PubMed Web of Science ®Google Scholar
• Vermeulen P. B., Gasparini G., Fox S. B., Toi M., Martin L., McCulloch P., Pezzella F., Viale G., Weidner N, Harris A. L., Dirix L. Y. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A(14)2474–2484
   PubMed Web of Science ®Google Scholar
• Senger D. R., Asch B. B., Smith B. D., Perruzzi C. A., Dvorak H. F. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature. 1983; 302(5910)714–715
   PubMed Web of Science ®Google Scholar
• Senger D. R., Perruzzi C. A., Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res. 1989; 9(5)1291–1299
   PubMed Web of Science ®Google Scholar
• Bautista D. S., Xuan J. W., Hota C., Chambers A. F., Harris J. F. Inhibition of Arg-Gly-Asp (RGD)- mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 1994; 269(37)23280–23285
   PubMed Web of Science ®Google Scholar
• Samanna V., Wei H., Ego-Osuala D., Chellaiah M. A. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp Cell Res. 2006; 312(12)2214–2230
   PubMed Web of Science ®Google Scholar
• Hirama M., Takahashi F., Takahashi K., Akutagawa S., Shimizu K., Soma S., Shimanuki Y., Nishio K., Fukuchi Y. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 2003; 198(1)107–117
   PubMed Web of Science ®Google Scholar
• Shijubo N., Uede T., Kon S., Nagata M., Abe S. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 2000; 11(2)135–146
   PubMed Web of Science ®Google Scholar
• Takano S., Tsuboi K., Tomono Y., Mitsui Y., Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer 2000; 82(12)1967–1973
   PubMed Web of Science ®Google Scholar
• Ito T., Hashimoto Y., Tanaka E., Kan T., Tsunoda S., Sato F., Higashiyama M., Okumura T., Shimada Y. An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res. 2006; 12(4)1308–1316
   PubMed Web of Science ®Google Scholar
• Sheng H., Shao J., Morrow J. D., Beauchamp R. D., DuBois R N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58(2)362–366
   PubMed Web of Science ®Google Scholar
• Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois, Cyclooxygenase R. N. regulates angiogenesis induced by colon cancer cells. Cell 1998; 93(5)705–716
   PubMed Web of Science ®Google Scholar
• Murata H., Kawano S., Tsuji S., Tsuji M., Sawaoka H., Kimura Y., Shiozaki H., Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94(2)451–455
   PubMed Web of Science ®Google Scholar
• Ohno R., Yoshinaga K., Fujita T., Hasegawa K., Iseki H., Tsunozaki H., Ichikawa W., Nihei Z., Sugihara K. Depth of invasion parallels increased cyclooxygenase- 2 levels in patients with gastric carcinoma. Cancer 2001; 91(10)1876–1881
   PubMed Web of Science ®Google Scholar
• Uefuji K., Ichikura T., Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol. 2001; 76(1)26–30
   PubMed Web of Science ®Google Scholar
• Joo Y. E., Rew J. S., Seo Y. H., Choi S. K., Kim Y. J., Park C. S., Kim S. J. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol. 2003; 37(1)28–33
   PubMed Web of Science ®Google Scholar
• Marrogi A. J., Travis W. D., Welsh J. A., Khan M. A., Rahim H., Tazelaar H., Pairolero P., Trastek V., Jett J., Caporaso N. E., Liotta L. A., Harris C C. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6(12)4739–4744
   PubMed Web of Science ®Google Scholar
• Tanigawa N., Amaya H., Matsumura M., Shimomatsuya T., Horiuchi T., Muraoka R., Iki M. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res. 1996; 56(11)2671–2676
   PubMed Web of Science ®Google Scholar
• Vlaykova T., Muhonen T., Hahka-Kemppinen M., Pyrhonen S., Jekunen A. Vascularity and prognosis of metastatic melanoma. Int J Cancer 1997; 74(3)326–329
   PubMed Web of Science ®Google Scholar
• Sulzbacher I., Birner P., Trieb K., Lang S., Chott A. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 2002; 441(4)345–349
   PubMed Web of Science ®Google Scholar
• Gao C., Guo H., Wei J., Mi Z., Wai P., Kuo P. C. S-nitrosylation of heterogeneous nuclear ribonucleoprotein A/B regulates osteopontin transcription in endotoxin-stimulated murine macrophages. J Biol Chem. 2004; 279(12)11236–11243
   PubMed Web of Science ®Google Scholar
• Parenti A., Morbidelli L., Cui X. L., Douglas J. G., Hood J. D., Granger H. J., Ledda F., Ziche M. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem. 1998; 273(7)4220–4226
   PubMed Web of Science ®Google Scholar
• Chun K. S., Cha H. H., Shin J. W., Na H. K., Park K. K., Chung W. Y., Surh Y. J. Nitric oxide induces expression of cyclooxygenase-2 in mouse skin through activation of NF-kappaB. Carcinogenesis. 2004; 25(3)445–454
   PubMed Web of Science ®Google Scholar
• Zhu Y., Denhardt D. T., Cao H., Sutphin P. D., Koong A. C., Giaccia A. J., Le Q. T. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 2005; 24(43)6555–6563
   PubMed Web of Science ®Google Scholar
• Wu G., Mannam A. P., Wu J., Kirbis S., Shie J. L., Chen C., Laham R. J., Sellke F. W., Li J. Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF. Am J Physiol Heart Circ Physiol 2003; 285(6)H2420–H2429
   PubMed Web of Science ®Google Scholar
• Wang Y. Q., Luk J. M., Ikeda K., Man K., Chu A. C., Kaneda K., Fan S. T. Regulatory role of vHL/HIF-1a in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun. 2004; 317(2)358–362
   PubMed Web of Science ®Google Scholar
• Scott J. A., Weir M. L., Wilson S. M., Xuan J. W., Chambers A. F., McCormack, Osteopontin D. G. inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am J Physiol 1998; 275(6 Pt 2)H2258–H2265
   PubMed Web of Science ®Google Scholar
• Attur M. G., Dave M. N., Stuchin S., Kowalski A. J., Steiner G., Abramson S. B., Denhardt D. T., Amin A. R. Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum 2001; 44(3)578–584
   PubMed Web of Science ®Google Scholar